Nymox details board changes and CEO share purchase

Nymox Pharmaceutical Corporation submitted a Form 6-K as a foreign private issuer.

Accepted by SEC EDGAR 03/27/2026 - 04:37 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Nymox Pharmaceutical Corporation submitted a Form 6-K as a foreign private issuer. The company reports that it issued a press release on March 27, 2026 describing upcoming changes to its Board of Directors, a share purchase by its Chief Executive Officer, and a remembrance note for its late Co-Chairman James G. Robinson. The press release is included as Exhibit 99.1 and is furnished, not filed, under the Securities Exchange Act of 1934.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Nymox Pharmaceutical Corporation (NYMXF) report in this Form 6-K?

Nymox Pharmaceutical Corporation reports that it issued a press release on March 27, 2026. The release covers upcoming Board changes, a CEO share purchase, and a remembrance of late Co-Chairman James G. Robinson.

What corporate events are mentioned for Nymox Pharmaceutical Corporation (NYMXF)?

The filing mentions upcoming changes to the Board of Directors, a share purchase by the Chief Executive Officer, and a note of remembrance for the company’s late Co-Chairman James G. Robinson in an attached press release.

How is the Nymox Pharmaceutical (NYMXF) press release treated under U.S. securities laws?

The press release attached as Exhibit 99.1 is furnished, not filed, under the Securities Exchange Act of 1934. It is explicitly stated that it is not deemed filed for purposes of Section 18 of that Act.

Who signed the Nymox Pharmaceutical Corporation (NYMXF) Form 6-K?

The Form 6-K was signed on behalf of Nymox Pharmaceutical Corporation by Paul Averback. He is identified in the document as the company’s President and Chief Executive Officer at the time of signing.

What is included as Exhibit 99.1 to Nymox Pharmaceutical’s (NYMXF) Form 6-K?

Exhibit 99.1 is a press release of Nymox Pharmaceutical Corporation dated March 27, 2026. The release discusses Board of Directors changes, a CEO share purchase, and a remembrance of late Co-Chairman James G. Robinson.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of March, 2026

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

Bay & Deveaux Streets, Nassau, The Bahamas

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On March 27, 2026, the Company issued a press release announcing upcoming changes to the Board of Directors, share purchase by the CEO, and a note of remembrance of the Company's late distinguished Co-Chairman James G. Robinson. This press release is furnished as Exhibit 99.1. The press release furnished as Exhibit 99.1 to this report on Form 6-K shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

EXHIBIT INDEX

Exhibit No.		Description

99.1		Press Release of Nymox Pharmaceutical Corporation, dated March 27, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 27, 2026

	NYMOX PHARMACEUTICAL CORPORATION

	By:	/s/ Paul Averback
	Name:	Paul Averback
	Title:	President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

EX-99.1 PRESS RELEASE 8.8 KB